Reduced steatosis, significantly decreased NASH-related biomarkers (ALT, AST, GGT). Improved fibrosis score (NFS, APRI score but not FIB-4). Exenatide was given orally at a dose of 10 μg per day the first 4 weeks, and continued up to 6 months at 20 μg per day (142).Decrease in ceramides. Downregulation in hepatic lipogenic genes and genes involved in inflammation and fibrosis (141). Here, GPT is linked to steatosis.